
Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE
Monte Rosa Therapeutics stock price today
Monte Rosa Therapeutics stock price monthly change
Monte Rosa Therapeutics stock price quarterly change
Monte Rosa Therapeutics stock price yearly change
Monte Rosa Therapeutics key metrics
Market Cap | 427.59M |
Enterprise value | 389.59M |
P/E | -3.65 |
EV/Sales | N/A |
EV/EBITDA | -3.85 |
Price/Sales | N/A |
Price/Book | 1.46 |
PEG ratio | -0.16 |
EPS | -2.51 |
Revenue | N/A |
EBITDA | -138.79M |
Income | -135.28M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMonte Rosa Therapeutics stock price history
Monte Rosa Therapeutics stock forecast
Monte Rosa Therapeutics financial statements
Jun 2023 | 0 | -35.17M | |
---|---|---|---|
Sep 2023 | 0 | -34.88M | |
Dec 2023 | 8.75M | -33.25M | -379.94% |
Mar 2024 | 1.06M | -31.96M | -3004.51% |
Mar 2024 | 1.06M | -31.96M | -3004.51% |
---|---|---|---|
Sep 2025 | 2.2M | -34.34M | -1561.24% |
Oct 2025 | 2.72M | -29.12M | -1070.23% |
Dec 2025 | 6.14M | -28.23M | -459.26% |
Analysts Price target
Financials & Ratios estimates
2023-11-09 | -0.75 | -0.7 |
---|---|---|
2024-03-14 | -0.57 | -0.58 |
2024-05-09 | -0.56 | -0.53 |
Jun 2023 | 278616000 | 64.96M | 23.32% |
---|---|---|---|
Sep 2023 | 252103000 | 67.57M | 26.81% |
Dec 2023 | 303755000 | 124.50M | 40.99% |
Mar 2024 | 266745999 | 114.22M | 42.82% |
Jun 2023 | -25.32M | 18.55M | 1.2M |
---|---|---|---|
Sep 2023 | -24.70M | 35.62M | 1.10M |
Dec 2023 | 29.63M | 14.29M | 25.17M |
Mar 2024 | -38.16M | 9.85M | 246K |
Monte Rosa Therapeutics alternative data
Aug 2023 | 133 |
---|---|
Sep 2023 | 133 |
Oct 2023 | 133 |
Nov 2023 | 133 |
Dec 2023 | 133 |
Jan 2024 | 133 |
Feb 2024 | 133 |
Mar 2024 | 133 |
Apr 2024 | 133 |
May 2024 | 133 |
Jun 2024 | 130 |
Jul 2024 | 130 |
Monte Rosa Therapeutics other data
Period | Buy | Sel |
---|---|---|
Jun 2024 | 0 | 1207 |
Jul 2024 | 0 | 1610 |
Sep 2024 | 0 | 1699779 |
Oct 2024 | 0 | 157895 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | VERSANT VENTURE CAPITAL VI, L.P. 10 percent owner | Common Stock | 52,305 | $9.08 | $475,034 | ||
Sale | VERSANT VENTURE CAPITAL VI, L.P. 10 percent owner | Common Stock | 15,600 | $9.41 | $146,796 | ||
Sale | VERSANT VENTURE CAPITAL VI, L.P. 10 percent owner | Common Stock | 89,990 | $9.66 | $869,213 | ||
Sale | VERSANT VENTURE CAPITAL VI, L.P. 10 percent owner | Common Stock | 1,132,566 | $6.53 | $7,395,656 | ||
Sale | VERSANT VENTURE CAPITAL VI, L.P. 10 percent owner | Common Stock | 9,269 | $6.16 | $57,097 | ||
Sale | VERSANT VENTURE CAPITAL VI, L.P. 10 percent owner | Common Stock | 16,047 | $6 | $96,314 | ||
Sale | VERSANT VENTURE CAPITAL VI, L.P. 10 percent owner | Common Stock | 541,897 | $6 | $3,251,382 | ||
Sale | DUNN EDMUND officer: Principal Accounting O.. | Common Stock | 1,610 | $3.83 | $6,166 | ||
Sale | DUNN EDMUND officer: Principal Accounting O.. | Common Stock | 1,207 | $4.04 | $4,876 | ||
Purchase | WALKER PAUL EDWARD 10 percent owner | Common Stock | 1,050,000 | $19 | $19,950,000 |
Insider | Compensation |
---|---|
Dr. Markus Warmuth M.D. (1971) Pres, Chief Executive Officer & Director | $899,170 |
Mr. Ajim A. Tamboli C.F.A. (1977) Chief Financial Officer | $404,690 |
-
What's the price of Monte Rosa Therapeutics stock today?
One share of Monte Rosa Therapeutics stock can currently be purchased for approximately $4.4.
-
When is Monte Rosa Therapeutics's next earnings date?
Unfortunately, Monte Rosa Therapeutics's (GLUE) next earnings date is currently unknown.
-
Does Monte Rosa Therapeutics pay dividends?
No, Monte Rosa Therapeutics does not pay dividends.
-
How much money does Monte Rosa Therapeutics make?
Monte Rosa Therapeutics has a market capitalization of 427.59M. Monte Rosa Therapeutics made a loss 135.35M US dollars in net income (profit) last year or -$0.53 on an earnings per share basis.
-
What is Monte Rosa Therapeutics's stock symbol?
Monte Rosa Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "GLUE".
-
What is Monte Rosa Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Monte Rosa Therapeutics?
Shares of Monte Rosa Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Monte Rosa Therapeutics's key executives?
Monte Rosa Therapeutics's management team includes the following people:
- Dr. Markus Warmuth M.D. Pres, Chief Executive Officer & Director(age: 54, pay: $899,170)
- Mr. Ajim A. Tamboli C.F.A. Chief Financial Officer(age: 48, pay: $404,690)
-
How many employees does Monte Rosa Therapeutics have?
As Jul 2024, Monte Rosa Therapeutics employs 130 workers, which is 2% less then previous quarter.
-
When Monte Rosa Therapeutics went public?
Monte Rosa Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 24 Jun 2021.
-
What is Monte Rosa Therapeutics's official website?
The official website for Monte Rosa Therapeutics is monterosatx.com.
-
Where are Monte Rosa Therapeutics's headquarters?
Monte Rosa Therapeutics is headquartered at 645 Summer Street, Boston, MA.
-
How can i contact Monte Rosa Therapeutics?
Monte Rosa Therapeutics's mailing address is 645 Summer Street, Boston, MA and company can be reached via phone at +61 79492643.
Monte Rosa Therapeutics company profile:

Monte Rosa Therapeutics, Inc.
monterosatx.comNASDAQ
133
Biotechnology
Healthcare
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Boston, MA 02210
CIK: 0001826457
ISIN: US61225M1027
CUSIP: 61225M102